Why the study?
The interpretation of branched-chain amino acid levels can be context-dependent, and it remains unclear whether abnormal levels can inform prognosis.
Do fasting serum BCAA levels predict mortality hazard in older adults with or without hypertension and diabetes mellitus?
Cohort (n=2,997)
Do fasting serum BCAA levels predict mortality hazard in older adults with or without hypertension and diabetes mellitus?
Hazard Ratio: 0.93
p-value: p=0.0002
Elevated BCAA levels are associated with improved survival in older adults without cardiometabolic disease, whereas dyshomeostatic levels increase mortality risk in those with hypertension or diabetes.
Branched-chain amino acids are critical metabolic intermediates that can indicate increased risk of cardiometabolic disease when levels are elevated or, alternatively, suggest sufficient mitochondrial energy metabolism and reserve in old age. The interpretation of BCAA levels can be context-dependent, and it remains unclear whether abnormal levels can inform prognosis. This prospective longitudinal study aimed to determine the interrelationship between mortality hazard and fasting serum BCAA levels among older men and women aged ≥65 years with or without hypertension and diabetes mellitus. At baseline (0Y), fasting serum BCAA concentration in 2997 community-living older men and women were measured. Approximately 14 years later (14Y), 860 study participants returned for repeat measurements. Deaths were analysed and classified into cardiovascular and non-cardiovascular causes using International Classification of Diseases codes. Survival analysis and multivariable Cox regression were performed. During a median follow-up of 17Y, 971 (78.6%) non-cardiovascular and 263 (21.4%) cardiovascular deaths occurred among 1235 (41.2%) deceased (median age, 85.8 years [IQR 81.7–89.7]). From 0Y to 14Y, BCAA levels declined in both sexes, whereas serum creatinine concentration increased (both p < 0.0001). In older adults without hypertension or diabetes mellitus, the relationship between mortality hazard and BCAA level was linear and above-median BCAA levels were associated with improved survival, whereas in the presence of cardiometabolic disease the relationship was U-shaped. Overall, adjusted Cox regression determined that each 10% increment in BCAA concentration was associated with a 7% (p = 0.0002) and 16% (p = 0.0057) reduction in mortality hazard estimated at 0Y and 14Y, respectively. Our findings suggested that abnormally high or low (dyshomeostatic) BCAA levels among older adults with hypertension and/or diabetes mellitus were associated with increased mortality, whereas in those with neither disease, increased BCAA levels was associated with improved survival, particularly in the oldest-old.
No takes yet. Share an insight, caveat, or question.
Fung et al. (2023) conducted a cohort in Hypertension and diabetes mellitus (presence or absence) (n=2,997). Fasting serum branched-chain amino acid (BCAA) levels vs. Lower BCAA levels was evaluated on Mortality (HR 0.93 (per 10% increment), p=0.0002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: